HotSpot Therapeutics debuts with $45 million to pursue allosteric inhibitors

The company claims its technology will allow it to access previously undruggable targets 

Source: NanoFocus - July 23, 2018 Category: Nanotechnology Authors: Lisa M. Jarvis Source Type: research